Equities

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

Actions
  • Price (EUR)10.35
  • Today's Change-0.76 / -6.84%
  • Shares traded2.00k
  • 1 Year change+47.79%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments331145212
Total Receivables, Net0.811618
Total Inventory3.912.893.62
Prepaid expenses9.049.864.22
Other current assets, total------
Total current assets345173238
Property, plant & equipment, net107.402.73
Goodwill, net------
Intangibles, net--023
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets355180263
LIABILITIES
Accounts payable6.505.927.39
Accrued expenses181715
Notes payable/short-term debt0100
Current portion long-term debt/capital leases--0.040.14
Other current liabilities, total391.211.07
Total current liabilities633524
Total long term debt02937
Total debt04037
Deferred income tax------
Minority interest------
Other liabilities, total262019
Total liabilities898479
SHAREHOLDERS EQUITY
Common stock0.050.030.03
Additional paid-in capital1,008767753
Retained earnings (accumulated deficit)(742)(671)(569)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.860.790.84
Total equity26696184
Total liabilities & shareholders' equity355180263
Total common shares outstanding493434
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.